A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy

Trial Profile

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Donaperminogene seltoplasmid (Primary)
  • Indications Diabetic neuropathies
  • Focus Registrational; Therapeutic Use
  • Sponsors ViroMed; VM BioPharma
  • Most Recent Events

    • 26 Jul 2017 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.
    • 26 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
    • 27 Jun 2016 According to a VM BioPharma media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top